Skip to main content
Clinical Trials/NCT04588064
NCT04588064
Completed
Not Applicable

Comparison of 18F-FDG and 68Ga-FAPI PET/CT in Patients with Lung Adenocarcinoma

The First Affiliated Hospital of Xiamen University1 site in 1 country63 target enrollmentJuly 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lung Adenocarcinoma
Sponsor
The First Affiliated Hospital of Xiamen University
Enrollment
63
Locations
1
Primary Endpoint
Cut-off value of SUVmax
Status
Completed
Last Updated
last year

Overview

Brief Summary

To evaluate the potential usefulness of 68Ga-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in lung adenocarcinoma, compared with 18F-FDG PET/CT.

Detailed Description

Participants with lung adenocarcinoma underwent contemporaneous 18F-FDG and 68Ga-FAPI PET/CT for an initial assessment. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FDG and 68Ga-FAPI PET/CT were calculated and compared to evaluate the diagnostic efficacy. In addition, the investigators further investigate the performance of 68Ga-FAPI PET/CT for differentiating invasive adenocarcinoma from adenocarcinoma in situ (pre-invasive lesion) or minimally invasive adenocarcinoma in participants with solitary ground-glass opacity nodules.

Registry
clinicaltrials.gov
Start Date
July 1, 2020
End Date
July 1, 2022
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • (i) aged ≥ 18 years, with newly detected GGNs ≤ 3 cm on LDCT and suspected to be lung cancer, and with no prior treatment;
  • (ii) who accepted undergoing paired 18F-FDG and 68Ga-FAPI-46 PET/CT, with completion within one week of each other;
  • (iii) with planned surgical resection within one month after PET/CT examinations;
  • (iv) with an ability to provide informed consent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria

  • (i) without surgical treatment;
  • (ii) receiving antitumor treatment prior to surgery;
  • (iii) whose postoperative pathology revealed adenocarcinoma beyond stage IA or benign pulmonary lesions;
  • (iv) with concurrent diagnosis of other malignant tumors;
  • (v) with poor image quality or lesions difficult to measure.

Outcomes

Primary Outcomes

Cut-off value of SUVmax

Time Frame: 30 days

Using the cut-off value of SUVmax derived from 68Ga-FAPI-46 PET to distinguish IAC from pre-invasive lesions (including atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), and minimally invasive adenocarcinoma (MIA)) in GGNs.

Secondary Outcomes

  • The area under the receiver operating characteristic (ROC) curve (AUC), accuracy, sensitivity, specificity, p-value [indicating accuracy exceeding the No-Information Rate], and kappa value(30 days)

Study Sites (1)

Loading locations...

Similar Trials